BAJAJ HEALTHCARE LIMITED
BAJAJHCARE · General/Diversified · NSE
₹303
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for BAJAJHCARE yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
30%
ROE
3.0%
Debt/Equity
0.47
WACC
11.1%
Market Cap
₹1,018 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
10.1%
Return on capital employed
EV / EBITDA
11.3×
Enterprise multiple
Debt / EBITDA
2.4×
Leverage vs earnings
Interest Coverage
2.5×
EBIT covers interest
Current Ratio
1.89×
Short-term liquidity
Asset Turnover
0.73×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-1.8%
3-year revenue growth
Revenue CAGR (5Y)
3.9%
5-year revenue growth
Ratio Trends
BAJAJHCARE · last 5 annual periods
ROE
3.0%
ROCE
10.1%
Operating Margin
—
Debt / Equity
0.47×
PE
24.0×
EV / EBITDA
11.7×
Historical Financials
BAJAJHCARE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹680 Cr | ₹646 Cr | ₹473 Cr | ₹543 Cr | ₹611 Cr | -2.6% |
| EBITDA | ₹118 Cr | ₹122 Cr | ₹43.8 Cr | ₹102 Cr | ₹78.7 Cr | -9.7% |
| EBIT | ₹102 Cr | ₹81.1 Cr | ₹13.0 Cr | — | — | -40.3% |
| PAT | ₹71.4 Cr | ₹43.0 Cr | ₹-83.8 Cr | ₹39.5 Cr | ₹15.8 Cr | -31.4% |
| EPS (diluted) | ₹25.87 | ₹15.59 | ₹-5.19 | — | — | — |
| CFO | ₹0.7 Cr | ₹-22.2 Cr | ₹92.3 Cr | ₹21.6 Cr | ₹58.1 Cr | +203.3% |
| CapEx | ₹-79.3 Cr | ₹-93.6 Cr | ₹-30.3 Cr | ₹-11.5 Cr | ₹-43.3 Cr | — |
| FCF | ₹-78.6 Cr | ₹-116 Cr | ₹62.0 Cr | ₹10.1 Cr | ₹14.7 Cr | — |
| Total Assets | ₹721 Cr | ₹898 Cr | ₹765 Cr | ₹833 Cr | ₹923 Cr | +6.4% |
| Total Debt | ₹257 Cr | ₹415 Cr | ₹333 Cr | ₹223 Cr | ₹249 Cr | -0.8% |
| Shareholders' Equity | ₹328 Cr | ₹368 Cr | ₹278 Cr | ₹466 Cr | ₹533 Cr | +12.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BAJAJHCARE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 LINCOLN LINCOLN PHARMA LTD | +34.2%+52.0% upside | 40 | Below Fair Value | 12.3% | — |
SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
JAGSNPHARM JAGSNPHARM | — | — | Pending | 15.6% | 28.1× |
INDSWFTLAB IND SWIFT LABORATORIES LT | -72.7%-42.1% upside | 22 | Above Fair Value | 3.2% | — |
 AMRUTANJAN AMRUTANJAN | — | — | Pending | 15.6% | 24.6× |
Click a ticker to view its fair-value analysis.
Dividend History
4 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹4.50/sh
Last payout
2025-09-19
₹1.00
Peak payout
₹1.50
Trailing yield
0.33%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of BAJAJHCARE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BAJAJHCARE →
Compare
Head-to-head with peers
Compare BAJAJHCARE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BAJAJHCARENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.